Laropiprant/niacin/simvastatin

Drug Profile

Laropiprant/niacin/simvastatin

Alternative Names: MK-0524B; MK-524B

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Merck & Co
  • Class Antihyperlipidaemics; Indoles; Naphthalenes; Nicotinic-acids; Small molecules
  • Mechanism of Action GPR109A receptor agonists; GPR109B receptor agonists; HMG-CoA reductase inhibitors; Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hyperlipidaemia

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Nov 2012 Discontinued - Phase-III for Hyperlipidaemia in Asia (PO)
  • 01 Nov 2012 Discontinued - Phase-III for Hyperlipidaemia in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top